ICI-192605

ICI-192605
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

ICI-192605 is a chemical compound that has been studied for its potential pharmacological effects, particularly as a selective antagonist of the 5-HT2 receptor. This compound was developed by Imperial Chemical Industries (ICI), a company known for its research in pharmaceuticals and chemicals.

Pharmacology[edit]

ICI-192605 is primarily known for its action as a selective antagonist of the 5-HT2 receptor, which is a subtype of the serotonin receptor. The 5-HT2 receptor is involved in various neurological processes, including mood regulation, perception, and cognition. By blocking this receptor, ICI-192605 can potentially alter these processes, making it a compound of interest in the study of psychiatric and neurological disorders.

Mechanism of Action[edit]

The mechanism of action of ICI-192605 involves its binding to the 5-HT2 receptor, preventing serotonin from activating this receptor. This antagonistic action can lead to a decrease in the downstream effects typically mediated by serotonin, such as neurotransmitter release and neuronal excitability.

Potential Applications[edit]

Research into ICI-192605 has suggested potential applications in the treatment of disorders such as schizophrenia, depression, and anxiety disorders. By modulating the serotonergic system, ICI-192605 could help in managing symptoms associated with these conditions.

Chemical Properties[edit]

ICI-192605 is characterized by its specific chemical structure, which allows it to selectively bind to the 5-HT2 receptor. The compound's chemical formula and molar mass are important for understanding its pharmacokinetics and pharmacodynamics.

Research and Development[edit]

The development of ICI-192605 was part of a broader effort to understand the role of serotonin receptors in the brain and to develop drugs that can selectively target these receptors. While ICI-192605 itself may not be used clinically, it has contributed to the understanding of serotonin receptor pharmacology and the development of other therapeutic agents.

Also see[edit]